Impact of Physical Activity on Successful Aging

January 27, 2017 updated by: prof. Federico Schena, Universita di Verona

Impact of Physical Activity on Successful Aging: Multidisciplinary Analysis of Mechanisms and Outcomes

Emerging literature suggests that vascular factors might be involved in the pathogenesis of Alzheimer's disease (AD). Other recent studies demonstrate the positive effects of physical activity on cognitive and behavioral disturbances of patients with AD. Therefore, it has been postulated that exercise enchantment in cerebral circulation is the physiological mechanism that link physical exercise and reduction of AD symptoms. Consequently, a program of physical activity could be considered one approach to counteract dementia by improving cerebrovascular health.

However at this moment, it is not clear if the progressive brain vascular dysfunction and hypoperfusion, associated with the β-amyloid deposition, might be reversed or stabilized by an exercise intervention.

The aim of this study is to assess, in patients with AD, the influence of physical exercise, compared to cognitive stimulation, on:

  • Cognitive function;
  • Independence in daily living and behavioral symptoms;
  • Vascular function Finally, to investigate the physiological processes on the basis of the motor parameters' changes, the performances of the patients will be compared with the performances of healthy young and old subjects.

MAIN OBJECTIVE: Investigate, in patients with Mild Cognitive Impairment (MCI) and AD, the effects of a physical activity program, or cognitive stimulation on global cognitive function.

SECONDARY OBJECTIVES: Investigate the effects of the two treatments on:

  • cognitive and motor performances,
  • independence in activities of daily living,
  • behavioral symptoms,
  • peripheral vascular function.

Study Overview

Detailed Description

STUDY DESIGN:

Randomised controlled, blinded clinical trial.

SUBJECTS:

The study will include 120 patients with definite diagnosis of MCI or AD and 30 young healthy subjects and 30 old healthy subjects referred to the Research Unit associated with the Department.

Patients will be regarded as suitable to participate if they fulfilled the following criteria:

  • Mini Mental State Examination (MMSE) ≥ 8;
  • Performance Oriented Mobility Assessment ≥ 19 (POMA).

Exclusion criteria will be:

  • presence of other concurrent neurological diseases;
  • presence of other orthopaedic diseases involving the lower limbs and/or interfering with standing position and/or walking;
  • presence of severe auditory and visual deficits not corrected;
  • abuse of alcohol or drugs;
  • psychiatric disorders,
  • severe behavioral disorders;
  • hearth and respiratory disease that interfere with the motor activity. The protocol was be approved by the local ethics committee with number 2389. All participants will perform a physiatric examination by a medical doctor of the Department of Neurological and Movement Sciences. Written inform consent will be obtained from all participants before inclusion in the study.

Participants who will meet the inclusion criteria will conduct a clinical and instrumental evaluation at enrollment (T0) and after 6 months ± 15 days after the first visit (T1). The assessment procedures will also be repeated after 3 months (T2) from T1.

ASSESSMENT PROCEDURES

Primary endpoints:

- score obtained in the Mini Mental State Examination.

Secondary endpoints:

- score obtained in a cognitive battery.

For MCI patients will be used:

  • Trial Making Test (Reitan,1958),
  • Rivermead Behavioral Memory Test (Wilson, 1989),
  • Tower of London (Shallice, 1982),
  • Dual Task (Della Sala et al., 1997),
  • Frontal Assessment Battery (Iavarone A et al., 2004).

For AD patients will be used:

  • Attention Matrix (Spinnler et al., 1987),
  • Alzheimer's Disease Assessment Scale (Rosen WG et al., 1984),
  • Frontal Assessment Battery (Iavarone A et al., 2004).

    - score obtained in a motor skills assessment composed by:

  • 6-Minute Walking Test (Ries JD et al., 2009),
  • gait analysis by GAITRite® System (Bilney B et al., 2003),
  • stabilometric assessments with Stability Line (Nashner LM and Peters JF, 1990),

    • score obtained in the test Instrumental Activity in Daily Living (Lawton MP and Brody EM, 1969),
    • score obtained in the test Neuropsychiatric Inventory (Cummings JL et al., 1994),
    • peripheral vascular function measured by doppler.

To evaluate the effectiveness of motor treatment, compared to a cognitive treatment on motor skills, cognitive skills, behavioral and autonomy in patients with cognitive decline, all patients will be evaluated by motor, cognitive, behavioral and autonomy scales, at baseline, after 6 months (T1), and after others 3 months (T2). A subgroup of 50% of patients will undergo instrumental procedures to investigate the effects of treatments on cerebral blood flow (arterial spin labeling).

TREATMENT PROCEDURES

The participants will be recruited and randomly assigned, according to the degree of cognitive decline, to one of the 3 groups (7-8 subjects):

  • Physical Activity group (PA group): It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
  • Cognitive treatment group (CT group): The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems The PA and CT groups will be homogeneous for clinical and demographic data, and participants will undergo 72 treatment group sessions, 60-minute/session, and 3 days/week for 6 consecutively months.

Both types of treatment will be balanced with different degrees of difficulty depending on the state of disease severity .

o The control groups (CG) will not receive any such treatment during the study and they will be evaluated by the same clinical and instrumental assessments.

Study Type

Interventional

Enrollment (Actual)

90

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years to 90 years (Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age ≥ 65 years;
  • Mini Mental State Examination (MMSE) ≥ 8;
  • Performance Oriented Mobility Assessment ≥ 19 (POMA).

Exclusion Criteria:

  • presence of other concurrent neurological diseases;
  • presence of other orthopaedic diseases involving the lower limbs and/or interfering with standing position and/or walking;
  • presence of severe auditory and visual deficits not corrected;
  • abuse of alcohol or drugs;
  • psychiatric disorders,
  • severe behavioral disorders;
  • hearth and respiratory disease that interfere with the motor activity.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Alzheimer's Disease (G1)
(G1) physical activity (PA)
It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
Experimental: Alzheimer's Disease (G2)
(G2) cognitive treatment (CT)
The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems
No Intervention: Healthy Old Subjects (G1)
Control group old
No Intervention: Healthy young Subjects (G2)
Control group young

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Mini Mental State Examination
Time Frame: 0-6-9 months (change will be assessed)
0-6-9 months (change will be assessed)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Trail Making Test
Time Frame: 0-6-9 months (change will be assessed)
For MCI patients (Reitan,1958)
0-6-9 months (change will be assessed)
Rivermead Behavioral Memory Test
Time Frame: 0-6-9 months (change will be assessed)
For MCI patients (Wilson, 1989)
0-6-9 months (change will be assessed)
Tower of London
Time Frame: 0-6-9 months (change will be assessed)
For MCI patients (Shallice, 1982)
0-6-9 months (change will be assessed)
Dual Task
Time Frame: 0-6-9 months (change will be assessed)
For MCI patients (Della Sala et al., 1997)
0-6-9 months (change will be assessed)
Frontal Assessment Battery
Time Frame: 0-6-9 months (change will be assessed)
(Iavarone A et al., 2004)
0-6-9 months (change will be assessed)
Attention Matrix
Time Frame: 0-6-9 months (change will be assessed)
For AD patients (Spinnler et al., 1987)
0-6-9 months (change will be assessed)
Alzheimer's Disease Assessment Scale
Time Frame: 0-6-9 months (change will be assessed)
For AD patients (Rosen WG et al., 1984)
0-6-9 months (change will be assessed)
6-Minute Walking Test
Time Frame: 0-6-9 months (change will be assessed)
(Ries JD et al., 2009)
0-6-9 months (change will be assessed)
gait analysis by GAITRite® System
Time Frame: 0-6-9 months (change will be assessed)
(Bilney B et al., 2003)
0-6-9 months (change will be assessed)
stabilometric assessments with Stability Line
Time Frame: 0-6-9 months (change will be assessed)
(Nashner LM and Peters JF, 1990),
0-6-9 months (change will be assessed)
Instrumental Activity in Daily Living Scale (IADL)
Time Frame: 0-6-9 months (change will be assessed)
0-6-9 months (change will be assessed)
Neuropsychiatric Inventory Scale (NPI)
Time Frame: 0-6-9 months (change will be assessed)
0-6-9 months (change will be assessed)
cerebral circulation
Time Frame: 0-6-9 months (change will be assessed)
measured MRI arterial spin labeling
0-6-9 months (change will be assessed)
peripheral vascular function
Time Frame: 0-6-9 months (change will be assessed)
measured by vascular doppler
0-6-9 months (change will be assessed)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Nicola Smania, Department of Neurological and Movement Sciences
  • Principal Investigator: Federico Schena, Department of Neurological and Movement Sciences

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2013

Primary Completion (Actual)

May 1, 2016

Study Completion (Actual)

October 1, 2016

Study Registration Dates

First Submitted

January 10, 2017

First Submitted That Met QC Criteria

January 24, 2017

First Posted (Estimate)

January 27, 2017

Study Record Updates

Last Update Posted (Estimate)

January 30, 2017

Last Update Submitted That Met QC Criteria

January 27, 2017

Last Verified

January 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Physical Activity

Clinical Trials on Physical activity (PA)

3
Subscribe